Lucira Health, Inc. Investors: Company Investigated by the Portnoy Law Firm

This post was originally published on this site

Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Lucira Health, Inc. (“Lucira” or the “Company”) (NASDAQ: LHDX) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email:, to discuss their legal rights, or click here to join the case via The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The investigation concerns whether Lucira and certain of its directors and/or officers have engaged in securities fraud or other unlawful business practices. Pre-market, Lucira issued a press release on October 8, 2021 reporting that its supply partner Copan Italia SPA had announced a recall of its FLOQSwabs, which were included in the LUCIRA COVID-19 All-In-One Test Kit, as well as its LUCIRA CHECK IT COVID-19 Test Kit. It was stated in this press release that “[a]ccording to Lucira’s records, Test Kits containing the recalled Copan swabs were distributed from April 22, 2021 through September 22, 2021,” and that the recalled Copan swabs should not be used and instead should be disposed. On October 8, 2021 Lucira’s stock price dropped sharply during intraday trading on this news, damaging investors.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising